Your browser doesn't support javascript.
loading
Investigating the impact of Tocilizumab, Sarilumab, and Anakinra on clinical outcomes in COVID-19: A systematic review and meta-analysis.
Jafari Abarghan, Yousef; Heiat, Mohammad; Jahangiri, Abolfazl; Hossein Peypar, Mohammad; Abdorrashidi, Mahdi; Tohidinia, Amirmohammad; Salesi, Mahmood; Tajik, Shahrzad; Farzaneh Dehkordi, Farnaz; Sedighian, Hamid.
Afiliación
  • Jafari Abarghan Y; Applied Microbiology Research Center, Biomedicine Technologies Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
  • Heiat M; Baqiyatallah Research Center for Gastroenterology and Liver Diseases (BRCGL), Clinical Sciences Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
  • Jahangiri A; Applied Microbiology Research Center, Biomedicine Technologies Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
  • Hossein Peypar M; Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran.
  • Abdorrashidi M; Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran.
  • Tohidinia A; Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran.
  • Salesi M; Chemical Injuries Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
  • Tajik S; Department of Biological Science, School of Sciences, Roudehen Branch, Islamic Azad University, Tehran, Iran.
  • Farzaneh Dehkordi F; Department of Biology, Ardabil Branch, Islamic Azad University, Ardabil, Iran.
  • Sedighian H; Department of Biological Science, School of Sciences, Roudehen Branch, Islamic Azad University, Tehran, Iran.
Int J Cardiol Heart Vasc ; 54: 101483, 2024 Oct.
Article en En | MEDLINE | ID: mdl-39221116
ABSTRACT

Background:

Monoclonal antibodies (mAbs) are currently under investigation as a potential therapeutic option for COVID-19. Clinical trials are examining their efficacy in lowering mortality rates and the requirement for mechanical ventilation (MV). It is necessary to conduct a thorough examination of current randomized controlled trials (RCTs) in order to provide more definitive evidence on their effectiveness for COVID-19 patients. This meta-analysis aims to analyze RCT results on the impact of three mAbs (Anakinra, Sarilumab, Tocilizumab) on COVID-19 patient outcomes.

Method:

The meta-analysis was conducted in accordance with the PRISMA guidelines. Eligible RCTs were conducted to evaluate the effectiveness of three mAbs in treating patients with COVID-19. These trials were identified by searching various databases up to April 1, 2024. In total, this meta-analysis incorporated 19 trials with a total of 8097 patients. Pooled relative risk and studies' heterogeneity were assessed by statistical analysis, which involved the use of fixed effects models and subgroup analysis.

Result:

The administration of mAbs (Tocilizumab, Sarilumab, and Anakinra) showed various results in the management of COVID-19 patients. While the overall pooled data did not reveal a significant reduction in the need for MV, the study found that the use of mAbs was associated with a decreased risk of clinical worsening (pooled relative risk 0.75, 95 % CI [0.59, 0.94], p = 0.01) and an increased probability of discharging COVID-19 patients by day 28 or 29 (pooled relative risk 1.17, 95 % CI [1.10, 1.26]). Notably, the subgroup analysis revealed that Tocilizumab had a significant effect in reducing the risk of clinical worsening compared to Sarilumab. Additionally, the analysis of mortality outcomes indicated that the administration of mAbs had the potential to decrease the overall risk of mortality over time (pooled RR 0.90, 95 % CI [0.83, 0.97], p = 0.01).

Conclusion:

In summary, our meta-analysis suggests that mAbs, particularly Tocilizumab, may play a valuable role in managing COVID-19 by reducing the risk of clinical worsening, improving hospital discharge rates, and decreasing mortality.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Int J Cardiol Heart Vasc Año: 2024 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Irlanda
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Int J Cardiol Heart Vasc Año: 2024 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Irlanda